Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 36

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 36
---
Financings

All
share and per-share amounts in the accompanying footnotes have been retroactively adjusted to reflect the Company’s 1-for-30 reverse
stock split.

In
October 2025, the Company entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007
per share, at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The gross
proceeds to the Company from the offering were approximately $1.8 million before deducting placement agent fees and other offering expenses
payable by the Company.

On
September 29, 2025, the Company consummated a best efforts public offering of an aggregate of (i) 1,047,694 shares of Common Stock and
(ii) pre-funded warrants to purchase up to 874,067 shares of Common Stock in lieu of shares of Common Stock. Each share was sold at a
public offering price of $2.50. Each pre-funded warrant was sold at a public offering price of $2.493. The total gross proceeds for the
transaction were approximately $4.8 million.

On
August 13, 2025, the Company entered into a securities purchase agreement with certain institutional and accredited investors, pursuant
to which the Company agreed to issue and sell in a private placement (i) 990 shares of the Company’s newly designated Series B
Convertible Preferred Stock, with a par value $0.001 per share and stated value of $1,000 per share, for gross proceeds to the Company
of $990,000, which were initially convertible into 143,476 shares of the Company’s Common Stock at an initial conversion price
of $6.90 per share and (ii) warrants to purchase up to 223,824 shares of the Company’s Common Stock at an exercise price of $10.56
per share of Common Stock.

20

On
August 13, 2025, the Company entered into a warrant inducement agreement with the holder of a warrant to purchase 15,000 shares of Common
Stock originally issued on August 5, 2024, with a current exercise price of $37.50 per share and a warrant to purchase 21,666 shares
of Common Stock originally issued on October 21, 2024, with a current exercise price of $45.00 per share, pursuant to which the Holder